Search Within

Neal Rosen

Formats
  1. Journal Article (226)
  2. Meeting Abstract (186)
  3. Conference Paper (7)
  4. Book Section (2)
  5. Editorial (2)
  6. Review (2)
  7. Research Letter (1)
Groups
  1. Breast Medicine Service (426)
  2. Department of Medicine (426)
  3. GSK Faculty (426)
  4. Molecular Pharmacology and Chemistry Program Faculty (426)
  5. Sloan Kettering Institute Faculty (426)
  6. Solid Tumor Oncology Division (426)

More Groups

People
  1. David Solit (155)
  2. Sarat Chandarlapaty (57)
  3. Howard Scher (44)
  4. Christine Pratilas (36)
  5. Elisa De Stanchina (36)
  6. Laura Sepp-Lorenzino (36)

More People

Years
  1. 2025 (2)
  2. 2024 (6)
  3. 2023 (2)
  4. 2022 (13)
  5. 2021 (13)
  6. 2020 (12)

More Years

Publications
  1. Cancer Research (99)
  2. Clinical Cancer Research (43)
  3. Proceedings of the American Association for Cancer Research Annual Meeting (36)
  4. Cancer Discovery (24)
  5. Journal of Clinical Oncology (23)
  6. Cancer Cell (15)

More Publications

Publishers
  1. American Association for Cancer Research (212)
  2. Nature Publishing Group (38)
  3. American Society of Clinical Oncology (24)
  4. Cell Press (19)
  5. Elsevier Inc. (17)
  6. National Academy of Sciences (11)

More Publishers

Results (426)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Genetic and pharmacological inhibition of P13 kinase signaling in vivo sensitizes tumors to EGFR inhibitors and to taxol
    Meeting Abstract

    She, Q. B.; Ye, Q.; She, Y.; Solit, D. B.; Rosen, N.
    Cancer Research (2006)

    Fulltext@MSK | Save
  • MAPK activation by B-RAF mutation or tyrosine kinase activation is associated with different patterns of feedback regulation that correlate with functional output of the pathway
    Meeting Abstract

    Pratilas, C. A.; Grbovic, O.; Sebolt-Leopold, J.; Rosen, N.; Solit, D. B.
    Cancer Research (2006)

    Fulltext@MSK | Save
  • IGF-1 rescues rapamycin-induced cell growth inhibition
    Meeting Abstract

    O'reilly, K. E.; She, Q. B.; Solit, D. B.; Rosen, N.
    Cancer Research (2006)

    Fulltext@MSK | Save
  • Phase I dose escalating trial of KOS-953 (heat shock protein 90 inhibitor) and trastuzumab (T)
    Meeting Abstract

    Modi, S.; Stopeck, A. T.; Gordon, M. S.; Solit, D.; Bagatell, R.; Ma, W.; Wheler, J.; Cropp, G. F.; Rosen, N.; Johnson, R. G. Jr; more...
    Cancer Research (2006)

    Fulltext@MSK | Save
  • Combined inhibition of PI3K/AKT and MAPK signaling is required to inhibit translational initiation and to induce apoptosis in human tumors
    Meeting Abstract

    She, Q. B.; Ye, Q.; Solit, D.; Rosen, N.
    EJC Supplements (2006)

    Fulltext@MSK | Save
  • Inhibition of Hsp90 function downregulates EGFR and sensitizes EGFR-mutant xenografts to paclitaxel
    Meeting Abstract

    Sawai, A.; Greulich, H.; Ye, Q.; Sellers, W.; Rosen, N.; Solit, D.
    EJC Supplements (2006)

    Fulltext@MSK | Save
  • B-RAF mutation is associated with altered patterns of negative feedback of MAPK signaling that correlate with increased output of the pathway and increased sensitivity to MEK inhibition
    Meeting Abstract

    Pratilas, C.; Grbovic, O.; Zhao, H.; Viale, A.; Solit, D.; Rosen, N.
    EJC Supplements (2006)

    Fulltext@MSK | Save
  • A pilot study to assess the tolerability and efficacy of RAD-001 (everolimus) with gefitinib in patients with recurrent glioblastorna multiforme (GBM)
    Meeting Abstract

    Nguyen, T. D.; Lassman, A. B.; Lis, E.; Rosen, N.; Shaffer, D. R.; Scher, H. I.; Deangelis, L. M.; Abrey, L. E.
    Journal of Clinical Oncology (2006)

    Fulltext@MSK | Save
  • A pilot study to assess the tolerability and efficacy of RAD-001 (everolimus) with gefitinib in patients with recurrent glioblastoma multiforme (GBM)
    Meeting Abstract

    Nguyen, T. D.; Lassman, A. B.; Lis, E.; Rosen, N.; Shaffer, D. R.; Scher, H. I.; Deangelis, L. M.; Abrey, L. E.
    Neuro-Oncology (2006)

    Fulltext@MSK | Save
  • Phase 2 trial of trastuzumab (T) and KOS-953 (17-AAG) in patients (pts) with Her2-positive breast cancer: Preliminary results
    Meeting Abstract

    Modi, S.; Stopeck, A.; Linden, H. M.; Sugarman, S.; Ma, W.; Solit, D.; Rosen, N.; Kersey, K.; Johnson, R. G.; Hannah, A. L.; more...
    Breast Cancer Research and Treatment (2006)

    Fulltext@MSK | Save